According to a market report by Lucintel, the future of the global microbiome therapeutics market looks promising with opportunities in the C. difficile, crohn’s disease, inflammatory bowel disease, and diabetes markets. The global microbiome therapeutics market is expected to grow with a CAGR of 35.3% from 2025 to 2031. The major drivers for this market are the increasing research into gut health therapies, the rising prevalence of chronic immune disorders, and the growing investment in microbiome based drugs.
A more
than 150-page report to understand trends, opportunity and forecast in global microbiome
therapeutics market to 2031 by type (FMT and microbiome drugs), application (C.
difficile, crohn’s disease, inflammatory bowel disease, diabetes, and others),
and region (North America, Europe, Asia Pacific, and the Rest of the World).
Lucintel
forecasts that, within the type category, FMT is expected to witness higher
growth over the forecast period.
Within the
application category, C. difficile is expected to witness the highest growth.
In terms
of region, APAC is expected to witness the highest growth over the forecast
period.
Download
sample by clicking on microbiome therapeutics
market.
OpenBiome,
Seres Therapeutics Inc., 4D Pharma plc., Locus Biosciences, Inc., Enterome SA,
Finch Therapeutics Group, Inc., Intralytix, Inc., Microbiotica, Second Genome,
Rebiotix Inc. are the major suppliers in
the microbiome therapeutics
market.
This unique research
report will enable you to make confident business decisions in this globally
competitive marketplace. For a detailed table of contents, contact Lucintel at
+1-972-636-5056 or write us at helpdesk@lucintel.com. To get access of more than 1000 reports at fraction of cost
visit Lucintel's Analytics
Dashboard.
About Lucintel
At Lucintel, we offer solutions for
you growth through game changer ideas and robust market &
unmet needs analysis. We are based in
Dallas, TX and have been a trusted advisor for 1,000+ clients for over 20
years. We are quoted in several publications like the Wall Street Journal,
ZACKS, and the Financial Times.
Contact:
Roy Almaguer
Lucintel
Dallas, Texas, USA
Email: roy.almaguer@lucintel.com
Tel. +1-972-636-5056
Explore Our Latest Publications
No comments:
Post a Comment